Assessing Biologics Adherence Behaviors Among Patients With Psoriasis Through Group-based Trajectory Models | 10191
Journal of Analytical & Bioanalytical Techniques
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The quartiles of proportion days covered (PDC) is a commonly used metric to examine adherence and health outcomes;
however, this metric cannot distinguish between different patterns of adherence. In this study, group-based trajectory
modeling (GBTM) was applied to study adherence behaviors of 3,249 psoriasis patients initiated on a biologic treatment during
a 1-year follow-up period. Four GBTM adherence groups were classified as high-to-high (Group 4), high-to-low (Group
3), medium-to-low (Group 2), and medium-to-medium (Group 1), based on the adherence curve changes. For comparison
purposes, four PDC groups were constructed: Group 4 (PDC≥75%), Group 3 (25%≤PDC<50%), Group 2 (PDC<25%), and
Group 1 (50%≤PDC<75%) . The majority of patients (97.9%) from PDC Group 2 were in Trajectory Group 2, and the majority
(96.4%) of those from PDC Group 4 were in Trajectory Group 4. The other two adherence groups showed different patterns:
25.3%, 17.2%, and 57.5% patients from PDC Group 3 fell into Trajectory Group 1, 2, and 3, respectively, and 70.8%, 23.6%, 5.7%
from PDC Group 1 fell into Trajectory Group 1, 3, and 4, respectively. The variances of adherence rates from corresponding PDC
and GBTM groups were compared and the results showed the GBTM groups had slightly less variation than the PDC groups,
indicating that the GBTM adherence groups were more homogeneous than the PDC groups. The study demonstrated that GBTM
may be a better approach to classifying patients in terms of adherence in outcome research.
Yunfeng Li is Research Analyst/Assistant Director in US Medical Affairs and Regulation Department in Novartis Pharmaceutical Corporation, focuses
on assessment of patient medications adherence measure, disease landscape analysis, treatment patterns, health economic and outcome research
etc. by using large medical claim database, patient reported outcomes (PRO) and electronic medical records (EMR). Prior to joining the Novartis,
he worked for health insurance and disease management companies to conduct patient profiling and clinical quality measurement for evaluation on
disease management programs. He completed his Ph.D. in Public Health from Columbia University in 2005.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals